Search Results
10
Everything
Search Filters
Organization
AKAMPION
New Clinical Data on BellaSeno’s Novel, Resorbable Breast Implants Presented at The Aesthetic MEET 2025
March 24, 2025 05:00 ET
|
AKAMPION
Presentation by Prof. Anand Deva highlights 87% breast volume retention and low complication rate in one-year patient follow-upSuccessful vascularization and vessel formation in two-year follow-up...
AMYRA Publishes Landmark Review Supporting New Gluten Digestion Approach for Celiac Disease
February 25, 2025 04:00 ET
|
AKAMPION
Findings highlight underexplored role of intestinal brush border in protein digestion, and its vulnerability to inflammatory damage in celiac disease Review discusses potential benefits of...
BellaSeno Successfully Completes Two Clinical Trials with Novel, Resorbable Breast Implants
January 14, 2025 04:00 ET
|
AKAMPION
One-year follow-up data confirm favorable safety profile of BellaSeno´s scaffolds compared to silicone implantsCompany plans expansion to primary breast augmentation and lumpectomy Leipzig, Germany/...
tiakis Biotech AG Receives Positive Scientific Advice from the U.S. FDA for Planned Phase II Trial of Tiprelestat
January 08, 2025 04:00 ET
|
AKAMPION
- tiakis and Stanford University are preparing for a Phase II in Pulmonary Arterial Hypertension (PAH) Kiel, Germany, January 8, 2025 – tiakis Biotech AG, a clinical-stage biopharmaceutical company...
Next-generation RNA company Inverna Therapeutics launched by Argobio and University of Southern Denmark
January 07, 2025 04:00 ET
|
AKAMPION
Novel paradigm for therapeutics based on RNA splicing modulationLead program in Huntington’s disease Denmark – Odense – 07/01/2025 – Inverna Therapeutics, a novel Danish biotech company at the...
tiakis Biotech AG Reports Clinical Phase Ib/II Trial Results of Tiprelestat for the Treatment of Hospitalized COVID-19 Patients
December 09, 2024 04:00 ET
|
AKAMPION
- Tiprelestat was safe and well tolerated, with initial signs of clinical efficacy Kiel, Germany, December 9, 2024 – tiakis Biotech AG, a clinical-stage biopharmaceutical company developing...
Thermosome Initiates Final Dose Level in Phase I Trial of Lead Compound THE001
December 04, 2024 04:00 ET
|
AKAMPION
Independent Data Safety Monitoring Board declared dose level 2 as safe and recommended escalation to final dose level 3 Munich, Germany – December 4, 2024 – Thermosome, a drug development company...
Thermosome Presents Encouraging Initial Clinical Data from Phase I Trial of Lead Compound THE001
November 19, 2024 04:00 ET
|
AKAMPION
THE001 safe and well tolerated in first two dose level, demonstrating encouraging signs of clinical activityData presented at The Connective Tissue Oncology Society (CTOS) Annual Meeting 2024 Munich,...
Ebenbuild Appoints Charles A. Taylor, PhD as Chairman of the Board
November 11, 2024 04:00 ET
|
AKAMPION
World renowned researcher and leader in predictive, simulation-based medicine to support further growth and strengthen footprint in the U.S. Munich, Germany, November 11, 2024 -- Ebenbuild, a company...
ANEUVO präsentiert wegweisendes Neuromodulationssystem ExaStim® auf der MEDICA 2024
November 06, 2024 04:00 ET
|
AKAMPION
Neuartiges Produkt mit FDA Breakthrough Device Designation zur Behandlung chronischer RückenmarksverletzungenTechnologie wird in Halle 10 / H44 vorgestellt Düsseldorf, Deutschland – 6....